Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas
Open Access
- 1 July 2021
- journal article
- research article
- Published by Frontiers Media SA in Pathology and Oncology Research
Abstract
Background: PD-L1 expression differs from 19 to 92% in various cancer subtypes. Its expression carries a worse prognostic value in various malignancies and could also be used as a predictive marker for immune checkpoint inhibitor response. This study aimed to explore the prevalence of PD-L1 expression in soft tissue sarcomas and the correlation of PD-L1 expression with clinicopathological features. Patients and Methods: The tissue samples of 50 patients with STS were tested for PD-L1 expression using immunohistochemistry (IHC). We followed a 6-step proportional scoring system. The patients were treated at Ain Shams University Hospital from 2011 to 2017. We also explored the correlation of PD-L1 expression with different clinical features of the patients. The chi-square test was used to calculate the differences among variables. Results: Twelve cases (24%) showed positive PD-L1 expression with the highest prevalence in rhabdomyosarcoma and desmoid tumors (2/2 and 2/3 cases, respectively), followed by GIST in 2/4 cases and liposarcoma in 3/11 cases. Patients with positive PD-L1 expression showed a trend for worse survival, with a median overall survival of 11 months vs. 19 months for patients with negative PD-L1 expression (p-value = 0.1) and a mean PFS of 6 months vs. 11 months for patients with negative PD-L1 expression (p-value = 0.1). However, these findings did not reach statistical significance. Conclusion: Although the results did not reach statistical significance due to the small number of cases, PD-L1 expression could represent a prognostic factor for poor outcome. Larger clinical trials are recommended for the validation of PD-L1 as a poor prognostic biomarker.Keywords
This publication has 19 references indexed in Scilit:
- PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue – prognostic implications and rationale for immunotherapyOncoImmunology, 2017
- Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomasLaboratory Investigation, 2016
- Prognostic implications of PD-L1 expression in patients with soft tissue sarcomaBMC Cancer, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma.Journal of Clinical Oncology, 2015
- Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironmentHuman Pathology, 2014
- WHO classification of soft tissue tumours: an update based on the 2013 (4th) editionPathology, 2014
- Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue SarcomasPLOS ONE, 2013
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- The Epidemiology of SarcomaClinical Sarcoma Research, 2012